Gener8 Maritime, Inc. (NYSE:GNRT) tinted gains of +1.69% (+0.1 points) to US$6.01. The volume of 0.19 Million shares climbed down over an trading activity of 336.82 Million shares. EPS ratio determined by looking at last 12 month figures is -2.78. Over the same time span, the stock marked US$6.94 as its best level and the lowest price reached was US$4.17. The corporation has a market cap of US$488.73 Million.

Gener8 Maritime, Inc. (NYSE:GNRT)’s earnings per share has been growing at a 4 percent rate over the past 5 year when average revenue increase was noted as 0.7 percent. The return on equity ratio or ROE stands at -17.7 percent while most common profitability ratio return on investment (ROI) was -3.4 percent. The company’s institutional ownership is monitored at 75.6 percent. The company’s net profit margin has achieved the current level of -98.7 percent and possesses 52.6 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 3 think it is Hold. Recently, analysts have updated the overall rating to 2.17. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Cross Country Healthcare, Inc. (NASDAQ:CCRN) is worth US$427.43 Million and has recently risen 1.69% to US$12.03. The latest exchange of 0.21 Million shares is below its average trading activity of 240.56 Million shares. The day began at US$11.77 but the price moved to US$11.77 at one point during the trading and finally capitulating to a session high of US$11.99. The stock tapped a 52-week high of US$14.65 while the mean 12-month price target for the shares is US$12.94.

Currently, the stock carries a price to earnings ratio of 8.83, a price to book ratio of 1.83, and a price to sales ratio of 0.49. For the past 5 years, the company’s revenue has grown 14.3%, while the company’s earnings per share has grown 31.1%. With an institutional ownership near 96.4%, it carries an earnings per share ratio of 1.36.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 6 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 3 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.5.